You are here

  • Home
  • Home

    • Investor Relations

    Home

    Message from our CEO

    812x408 Jeffrey Leiden_0.png

    Jeffrey Leiden, Chairman, President and CEO

    Events & Presentations
    1.png
    Events and Presentations
    3.png
    SEC Filings
    leadership
    Leadership

     

    Latest Press Releases

    Date Title and Summary
    Toggle Summary Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease
    - If approved, lumacaftor/ivacaftor will be the first medicine in Europe to treat the underlying cause of cystic fibrosis for approximately 1,500 young children with two copies of the F508del mutation - LONDON --(BUSINESS WIRE)--Nov. 16, 2018-- Vertex Pharmaceuticals (Europe) Limited today
    General Business
    Toggle Summary Vertex Announces European Authorization for Third Cystic Fibrosis Medicine SYMKEVI® (tezacaftor/ivacaftor), to be used in combination with ivacaftor (KALYDECO®), for People with CF Aged 12 and Older with Certain Mutations in the CFTR gene
    - A new treatment option for patients with two copies of the F508del mutation, the most common mutation in cystic fibrosis - - First medicine in the EU to treat the CFTR protein defect in patients who have one copy of the F508del mutation and one copy of one of 14 mutations that result in residual
    General Business
    Toggle Summary Vertex Reports Third-Quarter 2018 Financial Results
    -Third-quarter 2018 total CF product revenues of $783 million , a 42% increase compared to $550 million in the third quarter of 2017- -Company reiterates full-year 2018 total CF product revenue guidance of $2.9 to $3.0 billion ; reiterates full-year 2018 combined non-GAAP R&D and SG&A expense
    Financial

    Copyright West LLC. Minimum 15 minutes delayed.

    IR Contacts

    Institutional Analysts and Financial Analysts, please contact:
    michael
    Michael Partridge
    Senior Vice President, Investor Relations
    +1(617)-341-6108
    eric
    Eric Rojas
    Senior Director, Investor Relations
    +1(617)-961-7205
    zach
    Zach Barber
    Senior Director, Investor Relations
    +1(617)-341-6470
    leah
    Leah Gibson
    Associate Director, Investor Relations
    +1(617)-961-1507
    investor-faq
     
    Main Info
    Investorinfo@VRTX.com
    +1(617)-961-7163

    Contacting Vertex's Transfer Agent

    Communication regarding transfer requirements, lost certificates and changes of address should be directed to:

    Computershare Investor Services

    P.O. Box 43023
    Providence, RI 02940-3023
    Telephone: +1(781)-575-2879
    Fax: +1(781)-575-3605